Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Chiglitazar/Metformin Extended-Release FDC in Healthy Subjects
NCT07519265Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of chiglitazar and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum plasma concentration up to 72 hours, Area Under the Plasma Concentration-Time Curve from time zero to the last measurable concentration up to 72 hours and 1 more. Started Jul 2026; status: completed.
02
Drugs
chiglitazarliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07519265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519265.